Annovis Bio Inc. Secures 18-Month NYSE Compliance Extension
Annovis Bio Inc. (NYSE: ANVS) has been granted an 18-month period by the NYSE to meet listing requirements, ensuring continued trading of its shares while it advances therapies for neurodegenerative diseases.
Annovis Bio Inc. (NYSE: ANVS), a clinical-stage platform company focused on developing treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's, has received an 18-month compliance extension from the New York Stock Exchange. This extension, effective from March 26, 2025, allows the company additional time to meet the NYSE's minimum market capitalization and stockholders' equity requirements. Annovis Bio's shares will continue to be listed and traded on the NYSE during this period, contingent upon the company adhering to the milestones set forth in its compliance plan and maintaining all other listing standards.
The NYSE's decision underscores the potential of Annovis Bio's innovative approach to targeting multiple neurotoxic proteins, aiming to restore brain function and enhance patients' lives. This development is significant for investors and patients alike, as it provides the company with a clear pathway to maintain its listing status while advancing its clinical programs. For more details, visit https://ibn.fm/D9Yzt.